Retatrutide Triple Agonist: GLP-1 GIP Glucagon Mechanism
Retatrutide (LY3437943) is an experimental triple receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors — Phase 2 clinical trial data published in the NEJM in 2023 showed approximately 24% mean body weight reduction at 48 weeks in the highest-dose cohort, exceeding outcomes from single or dual agonist compounds in comparable timeframes.
Triple Agonist Receptor Comparison
| Receptor | Primary Effect | Retatrutide | Semaglutide | Tirzepatide |
|---|---|---|---|---|
| GLP-1R | Appetite suppression, insulin secretion | Yes (agonist) | Yes (agonist) | Yes (agonist) |
| GIPR | Incretin enhancement, adipose effects | Yes (agonist) | No | Yes (agonist) |
| Glucagon R (GCGR) | Thermogenesis, hepatic glucose, EE | Yes (agonist) | No | No |
| Weight loss (Ph2, 48w) | Maximum observed | ~24% (12mg dose) | ~15% (Wegovy) | ~22.5% (15mg, Ph3) |
| Mechanism advantage | Additional metabolic axis | Three pathways | One pathway | Two pathways |
Mechanism: Triple Receptor Pharmacology
Retatrutide (LY3437943) is a single synthetic peptide engineered to function as a triagonist across three distinct G-protein-coupled receptors. GLP-1R activation suppresses appetite and stimulates glucose-dependent insulin secretion. GIPR activation enhances incretin signaling and may potentiate GLP-1R-driven effects on adipose tissue. GCGR activation increases hepatic glucose output, thermogenesis, and resting energy expenditure. The simultaneous engagement of all three pathways creates a synergistic metabolic effect hypothesized to exceed single or dual agonist approaches.
Phase 2 NEJM Data (2023)
The Phase 2 trial (Jastreboff et al., NEJM 2023) enrolled adults with obesity (BMI 30-50) randomized to weekly subcutaneous retatrutide (1-12 mg) or placebo for 48 weeks. Key results: ~24% mean weight loss at 12 mg dose at 48 weeks, dose-dependent response from ~8.7% (1mg) to ~24.2% (12mg), and no plateau observed at week 48, suggesting continued efficacy trajectory. The trial showed retatrutide reduced cardiovascular risk markers (blood pressure, lipids, waist circumference) significantly versus placebo. Phase 3 trials are ongoing as of 2025.
Research Note
Retatrutide is an investigational compound (IND status). It has no approved human therapeutic application as of 2025. All information is for research context only. Phase 3 trial results are pending. Available at biohackslabs.com for research purposes under appropriate institutional oversight.
FAQ
What makes retatrutide different from semaglutide and tirzepatide?
Retatrutide adds glucagon receptor (GCGR) agonism to the GLP-1R and GIPR targeting of tirzepatide. The glucagon receptor arm increases thermogenesis and energy expenditure, adding a caloric-burn component absent from GLP-1 and GIP-only approaches. Phase 2 data shows this third agonist arm contributes to greater weight loss than dual agonism — ~24% vs. ~22.5% for tirzepatide's Phase 3 maximum.
What were the main findings of the retatrutide Phase 2 NEJM trial?
The 2023 NEJM Phase 2 trial (Jastreboff et al.) showed ~24% mean body weight reduction at 48 weeks in the 12 mg cohort. All active dose groups showed significantly greater weight loss than placebo. The response was dose-dependent and showed no plateau at week 48. Cardiovascular risk markers improved significantly. Adverse events were primarily GI. Phase 3 results are pending.